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Abstract
There can be a tendency for investigators to disregard or explain away null or negative results in prevention science trials.
Examples include not publicizing findings, conducting spurious subgroup analyses, or attributing the outcome post hoc to real or
perceived weaknesses in trial design or intervention implementation. This is unhelpful for several reasons, not least that it skews
the evidence base, contributes to research “waste”, undermines respect for science, and stifles creativity in intervention devel-
opment. In this paper, we identify possible policy and practice responses when interventions have null (ineffective) or negative
(harmful) results, and argue that these are influenced by: the intervention itself (e.g., stage of gestation, perceived importance);
trial design, conduct, and results (e.g., pattern of null/negative effects, internal and external validity); context (e.g., wider
evidence base, state of policy); and individual perspectives and interests (e.g., stake in the intervention). We advance several
strategies to promote more informative null or negative effect trials and enable learning from such results, focusing on changes to
culture, process, intervention design, trial design, and environment.
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Introduction
In his best-selling book, Black Box Thinking, Matthew Syed
(2015) argues that aviation is much better than other fields in
acknowledging and learning from performance failure. If an
aeroplane crashes, the black box containing essential flight
data is recovered, the data are analyzed, and any ensuing les-
sons are shared rapidly across the industry in order to improve
engineering practice or pilot behavior and reduce the risk of a
repeat event. He contrasts this with healthcare, contending that
there can be a tendency to cover up or explain away treatment
that is ineffective or harmful, or at least not to use this valuable
information as an opportunity to learn and contribute to con-
tinuous improvement. We think there is a danger of similarly
unhelpful behavior in prevention science when randomized
controlled trials1 find a null or negative effect, and use this
article to explore how to foster a more constructive approach.
As will be seen, this might mean challenging the value of
different types of research design in prevention science and
what they can bring to improving the knowledge base from
which learning can take place.
We recognize that there are complexities when trying to iden-
tify null or negative effect trials owing to issues with methodo-
logical quality and the pattern of results; taking the extremes,
there is a world of difference between a well-conducted trial
showing no effect on any measure of any outcome and a poorly
executed trial showing no effect on the primary outcome but
small effects on some measures of some secondary outcomes.
The picture is further muddied by reporting practices that claim
an effect when there is none. For the purposes of this article, we
define null effect trials in terms of failure to disprove the null
1 In this article, we refer primarily to superiority trials investigating the hy-
pothesized added value of an innovation/intervention over a services as usual
comparator. But the arguments may also apply to null results from equivalence
or non-inferiority trials, which suggest that the new intervention is likely to be
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hypothesis on the primary outcome, despite what the authors
may say or do, and negative effect trials as those that find a
negative effect on the primary outcome.
Our interest in this subject was triggered by our experience of
conducting several null effect superiority trials (Berry et al. 2016;
Lloyd et al. 2018; Axford et al. 2020a, b, c). This prompted us to
reflect on how we and other stakeholders responded, the relative
value of the results (including whether they would even get pub-
lished), and, in our (NA, TH) darker moments, whether the pri-
mary outcome meant a null effect was inevitable, whether the
research design limited learning, and even whether the trials
should have gone ahead in the first place. But our experience
and concerns are not uncommon (Bonafide and Keren 2018;
Oldehinkel 2018); a significant and possibly growing proportion
of trials in prevention science and beyond (e.g., Kaplan and Irvin
2015) find no or even harmful effects.
Several explanations of this trend have been offered: (i)
trials are conducted and reported more rigorously than previ-
ously owing to the advance publication of methods via online
registries and protocols, the application of standards of evi-
dence (e.g., Gottfredson et al. 2015), and the wide uptake by
journals of reporting guidelines (Schulz et al. 2010); (ii) ser-
vices as usual—the norm for control conditions—are improv-
ing, in part informed by results from earlier trials (the so-called
“rising tide phenomenon”—Chen et al. 2016); (iii) an increas-
ing number of trials are replication studies in new contexts that
were not considered in the original intervention design and
which, therefore, may not be favorable to finding positive
effects; (iv) there are more independent trials with no involve-
ment from program developers, who may have exerted delib-
erate or inadvertent influence on program delivery or trial
methodology in the original studies and therefore inflated
the effect (Eisner 2009; Gorman 2018); and (v) intervention
developers and purveyors increasingly perceive a need to be
endorsed by evidence-based program (EBP registries) in order
to secure funding, which risks trialing programs prematurely
(before establishing acceptability and feasibility).
In this context, it would be remiss if, as a field, we did not
reflect on how to learn from well-conducted null and negative
effect trials, particularly because how we respond affects not just
what happens after a trial but how we think about and design
interventions and tests of interventions. Yet widely used guid-
ance on developing and evaluating complex interventions (Craig
et al. 2008), and the draft update of that guidance which was
distributed for consultation in 2019,2 make next to no direct
reference to how to prepare for, consider and respond to null or
negative results. Guidance is being developed on what to do next
with effective interventions (Evans et al. 2019) but not, to our
knowledge, what to do with those found to be ineffective. In
short, there is a gap which this article seeks to help address.
In what follows, we describe how researchers often re-
spond to null or negative trial results and the implications of
their responses, set out what stakeholders might decide to do
with the intervention following the results, hypothesize what
influences those decisions, and finally propose a series of
actions to promote learning from null or negative effect trial
results. The suggested steps are designed to minimize the like-
lihood of unhelpful null effect trials—for example, those that
are poorly designed or provide little or no explanation for the
findings—and increase the proportion of trials which, even if
they have null or negative effect findings, advance our learn-
ing. We draw on examples from our own and other people’s
work in prevention science.
Making Sense of the Trial Findings
There seem to be seven common investigator responses to null
or negative effect trials in prevention science and beyond
(Table 1). The evidence for some of these is compelling; for
example, several extensive reviews covering a range of disci-
plines demonstrate publication bias (Hopewell et al. 2009;
Duyx et al. 2017; Chow and Eckholm 2018). For others, such
as forecasting delayed or sleeper effects, our observations are
based on our own and others’ experience of reviewing pro-
grams for EBP registries (e.g., Martin et al. 2018).3We readily
acknowledge that the problems identified, such as failure to
publish and conducting spurious subgroup analyses, are not
unique to prevention science (Rosenthal 1979; Kasenda et al.
2014). Nor are we suggesting that researchers seek to be un-
derhand. They (we) are part of a system and wider culture
involving multiple players (e.g., developers, funders, policy-
makers, commissioners, publishers, universities), so their
(our) responses can be seen as rational acts in response to a
complex set of incentives and constraints.
It is important to acknowledge that the appropriateness of
several of the behaviors identified is context-dependent,
meaning that they can be acceptable, even desirable. For in-
stance, if the trial quality does not meet the necessary stan-
dards of evidence such as those upheld by Blueprints for
Positive Youth Development (Mihalic and Elliott 2015), it is
appropriate that limitations to trial design or conduct cast
doubt on the results. Similarly, context is dynamic and may
change in unpredictable ways during the lengthy period of
developing, piloting, and testing a complex intervention
(Moore et al. 2019), such that it undermines intervention ef-
fectiveness. Moreover, forecasting delayed effects may be
reasonable if there are good theoretical or empirical grounds
to justify it (Hill et al. 2016)—for example, if effects were
2 https://www.gla.ac.uk/researchinstitutes/healthwellbeing/news/
hawkeye2018onwards/march2019/headline_641840_en.html
3 Our experience has been with: Blueprints for Healthy Youth Development;
the Early Intervention Foundation Guidebook; Project Oracle; the EMCDDA
XChange database; Evidence2Success; and Investing in Children.
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found for proposed mediators, or (non-significant) trends fa-
vored the intervention for aspects of development known to
emerge more strongly as children mature. Since the impact of
population-level interventions can take time to materialize, it
Table 1 Common researcher responses to finding null or negative effects in prevention science trials
Response Effect Legitimacy
1. Don’t publish: Researchers may not report null or
negative findings, either because results papers
are never submitted or because they are but
scientific journals are not interested in publishing
them (and the researcher gives up trying to get
results into the public domain).
This contributes to a skewed impression of “what
works” because the studies do not get picked up in
systematic reviews and meta-analyses;
specifically, evidence of effectiveness is likely to
be exaggerated.
Failure to submit a results paper for publication is not
necessarily a deliberate act, rather it can occur
through inertia (although when an author is
involved in intervention design or dissemination,
this distinction becomes blurred). Journal editors
and reviewers tend not to say that a lack of effect
is the reason for rejection, but null effects rarely
constitute the “ground-breaking” findings that
journals invariably aspire to publish.
2. Embark on fishing trips: Researchers may embark
on “fishing trips” to find evidence of impact.
Usually this entails conducting spurious analyses
in search of ad hoc subgroup effects.
The chances of finding false-positive results from a
single dataset increase as more hypotheses are
tested, so this practice can produce misleading
results.
Moderator analyses specified a priori in the trial
protocol or statistical analysis plan can be
suitable, even if they are exploratory and
acknowledged to be underpowered. However,
there is widespread agreement that it is
inappropriate to conduct ad hoc or theoretically
uninformed moderator analyses in an attempt to
find a positive effect for a subgroup.
3. “Cherry pick” positive results: In the context of
predominantly null or negative results,
researchers may single out any positive result,
however small or practically insignificant, and
accord it unwarranted prominence in the reporting
of findings.
This creates the appearance of effectiveness,
especially if the findings are “spun” in the
write-up (e.g., by referring to “positive effects” in
the abstract and relegating information about the
lack of effect to the body text).
Given the difficulty of publishing null or negative
findings, this response is unsurprising but
problematic when it concerns any of the
following: a secondary outcome or mediator; an
interim data collection point; an outcome with
marginal statistical significance (or the level of
statistical acceptability is changed to make it
“significant”); or a tiny effect that is unlikely to be
of practical or clinical significance (even if it is
statistically significant).
4. Focus on methodological limitations: Researchers
may criticize measures or other aspects of trial
design or conduct, implying that the test was
unfair, or insufficiently rigorous, and that it
therefore failed to uncover the “true” effectiveness
of the intervention.
This casts doubt on the veracity of the findings (even
when that is unfair), leading the reader to
conclude that the intervention is potentially
effective or of unknown effectiveness.
It is reasonable to identify limitations to trial
methodology when reporting results, and for
interested observers to critique the methods.
Limitations in design or conduct might present a
valid explanation for the lack of positive effects,
with important implications for the interpretation
of findings and conduct of future research.
However, it is disingenuous to identify such
problems only once results are known.
5. Focus on poor implementation: Researchers may
attribute the null effect to a failure to implement
the intervention with acceptable fidelity. To
support the argument, extra analyses may be
conducted to show that effects are observed when
fidelity is stronger.
This suggests that the intervention would be
effective if delivered as intended.
There is strong evidence for a positive association
between fidelity and outcomes, so exploring this
relationship is reasonable. However, care is
needed not to use fidelity as an excuse once
outcome results are known. Moreover, fidelity x
outcome analyses should compare “compliers” in
the intervention arm with a comparable group in
the control arm (those who would have complied
had they been offered the intervention) to avoid
spurious positive associations.
6. Focus on unsuitable context: Researchers may
contend that aspects of the context (e.g.,
organizational, cultural, political, economic) were
unsuitable and help to explain why the
intervention did not “work”.
This argument can be deployed to suggest that the
intervention is effective but that it did not work
here; put crudely, the problem is with the context
not the intervention.
Contextual arguments may be legitimate, and can
help with thinking about how to improve
intervention development and implementation
planning. However, they should not be used to
cast doubt unfairly on null or negative effect
findings, particularly if contextual issues were not
considered before the findings were known.
7. Forecast delayed or “sleeper” effects: On failing
to find effects at planned time points, researchers
may argue that the study timeframe was too short
and that positive effects will only become
apparent in the future.
This argument can be used to imply that the
intervention is effective but it was too soon to
observe those positive effects.
Forecasting delayed effects may be reasonable if
there are good theoretical or empirical grounds to
justify it (e.g., observed effects on proposed
mediators). When these are not present, it can cast
doubt on null results unfairly, particularly in the
absence of the means or intention of investigating
longer-term effects.
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is arguable that they should not be judged against traditional
benchmarks of efficacy (Greenberg and Abenavoli 2017).
Finally, attributing lack of effect to sample characteristics,
say level of baseline difficulties, may be apposite if supported
by exploratory moderator effects and the wider literature on
the effectiveness of that category of intervention.
Nevertheless, both individually and collectively, unhelpful
researcher responses to null or negative trial results limit learn-
ing. First, by unfairly casting doubt on robust findings, or
artificially creating or inflating positive results, it contributes
to a skewed impression of “what works” in a given subject
area, inadvertently suggesting that some forms of intervention
are more effective than they are (de Vries et al. 2018). This has
the potential to cause harm. While there are techniques in
meta-analysis to identify and compensate for publication bias
(funnel plot, trim and fill algorithm, fail safe N), they are
necessarily imperfect (Carter et al. 2019). Second, it contrib-
utes to research “waste”, which can increase risk and reduce
benefits for service users. Accurate knowledge of earlier null
or negative findings helps make future research more suitable
and may even render some proposed studies unnecessary and
irrelevant (Ioannidis et al. 2014). Third, it risks undermining
the credibility of prevention science. Critics have highlighted
what they perceive to be behaviors that artificially inflate re-
ported intervention effectiveness (e.g., Gorman 2014); we
should not ignore the issues. Fourth, it fosters a fear of null
or negative results, which in turn stifles creativity and new
approaches to intervention development and evaluation.
Deciding What to Do with the Intervention
When a rigorous trial shows that an intervention is not effec-
tive, or that it is harmful, there are essentially three options for
what to do with the intervention. Depending on the context,
they may or may not represent appropriate learning.
The first possible response is to continue to commission or
deliver the intervention. Stakeholders might accept the null or
negative results but conclude that there are no better alterna-
tives, or that the intervention is commendable for reasons
besides its (non-)effect on outcomes. For example, despite
the lack of effect in a trial of the PATHS social-emotional
learning program in one city in the UK (Berry et al. 2016),
the intervention continued to be commissioned in local
schools for a further 3 years, at least in part because coaches,
teachers, and students liked it. Of course, continuing to deliver
the interventionmay also happen if the results are not accepted
by commissioners or are explained away by researchers.
A second response is to stop delivering and/or refining the
intervention. This might take the form of decommissioning an
established intervention or, if evidence accumulates from sev-
eral null or negative effect trials of essentially similar programs
albeit with different heritage or branding, de-implementing a
class of interventions (Norton and Chambers 2020). Of course,
if an intervention only existed as part of a trial, as in the school-
based obesity prevention program tested in the Healthy
Lifestyles Program (HeLP) trial (Lloyd et al. 2018), there
may be nothing to decommission, but further development
might cease. Additionally, when evidence from numerous null
or negative effect trials accumulates, developers of health
guidelines, such as the National Institute for Health and Care
Excellence (NICE) in the UK, may issue “do not do” recom-
mendations for clinical practices that should be discontinued or
not used routinely.
A third response is to adapt the intervention and then test
those changes. The rationale is that the trial results are broadly
trustworthy and yield important lessons that need to be acted
upon. In such cases, it is deemed premature to cease delivery
but continuing with the intervention unchanged is not viable.
In this way, the trial results are used as a platform for inten-
tionally improving the intervention. Decisions about what to
adjust are likely to be informed not only by outcome patterns
but also, where available, by process evaluation results, not to
mention wider evidence and expert opinion. Examples of this
option include the reworking of a group parenting program
(Ghate 2018) following a null effect trial (Simkiss et al. 2013)
and the rapid cycle testing of adaptations to the Family Nurse
Partnership home visiting program (FNP National Unit and
Dartington Service Design Lab 2020) following disappointing
trial results (Robling et al. 2016).
Such practice and policy decisions arise from a range of
stakeholder responses which, we hypothesize, are shaped by
the following four sets of potentially competing and
interacting factors (Table 2). Exactly how these impact on
decision-making is complex: their importance will vary by
stakeholder and may change over time.We have derived these
factors from our collective experience of responding to trials
in which we have been directly involved as well as from our
observations of other researchers and stakeholders.
The Intervention
An important issue is where the intervention is in its gestation.
Finding a lack of effect early in its development is arguably
less of an issue, and therefore easier to deal with, than if the
intervention is considered to be mature and commissioned
widely; the emphasis for newly developed interventions can
be put on learning and re-design as there is little, if anything,
to de-implement. Indeed, guidance on developing and evalu-
ating complex interventions includes feasibility and piloting
stage as a critical stage in the process (Craig et al. 2008).
A related factor concerns the profile and perceived im-
portance of the intervention. If it is well established or
politically important, for instance because it has been in-
troduced by or received significant funding from govern-
ment, it may be “too big to fail”, leading perhaps to a
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temptation to dismiss the results or plow on regardless
with implementation and scale-up.
A further intervention-related factor is the degree to
which it is possible to implement the intervention easily
and well and whether it is acceptable to practitioners
and users. An intervention that is well received or su-
perior to its competitors in these respects may be more
likely to continue to be commissioned, despite trial re-
sults showing no effect (see the PATHS example
above).
Finally, the outcome(s) that the intervention seeks to ad-
dress influences how trial results are treated. Specifically,
some outcomes might be regarded as more important than
others, for instance in terms of threat to health or cost to soci-
ety if not achieved, such that null or negative results spur
stakeholders into action in terms of discontinuing or modify-
ing the intervention.
Trial Design, Conduct, and Results
An assessment of the quality of the evaluation design and
conduct likely has a bearing on stakeholders’ responses to null
or negative trial results, since this affects whether the results
need to be taken seriously—good internal validity—or in-
stead should be viewed with caution. Such assessments may
be conscious and well informed, as when trials are reviewed
formally against standards of evidence for the purposes of
populating online registries of EBPs, or arrived at rather more
subliminally or casually—for example, based on the per-
ceived caliber of research team members or the institutions
they represent.
The pattern of the null or negative effects is also predicted
to be an important factor: what proportion of outcomes are
affected, and at what time points; are they primary and/or
secondary; how important are any positive effects (even if
Table 2 Influences on what happens to an intervention following a null or negative effect trial
Factor Continued or future delivery of the intervention in
its current form is more likely
Continued or future delivery of the intervention in
its current form is less likely
The intervention
Stage of gestation Intervention is mature and widely commissioned Intervention is new or early in its development
Perceived importance Well established and politically important Lower profile and limited political importance
Implementation
feasibility/acceptability
Easy to deliver well, liked by practitioners/users Hard to deliver well, disliked by practitioners/users
Outcome(s) targeted Considered important (is a potential threat to health) Considered less important (not a threat to health)
Trial design, conduct, and results
Quality of trial design and
conduct
Concerns about quality undermine confidence in results Judged to be high quality and reliable
Pattern of outcome results Somewhat inconsistent or inconclusive Consistent and conclusive null/negative results
Context in which trial was
conducted
Deemed significantly different to new/current context Deemed to be similar to new/current context
Insight into reasons for the
result
Explained by methodological or delivery issues No reason to doubt or explain away the result
Nature of the control
condition




Multiple other trials with positive effects No other trials, or other evidence equivocal
Wider evidence base Similar interventions not obviously superior Similar interventions show positive effects
Policy and practice
imperatives
Need to do something, and nothing clearly superior Some discretion about acting, or superior alternatives
Political and economic
situation




Strong psychological or financial investment Weaker investment, permitting more detached stance
Outlook on evidence
(particularly trials)
Skeptical about evidence-based practice and/or trials Sympathetic towards evidence-based practice/trials
a Only applies to existing interventions, not those delivered solely in the context of a trial
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few), whether theoretically (e.g., hypothesized mediators,
knowledge vs. behavior) or in terms of the perceived veracity
of the measure (e.g., independent observation vs. self-report);
and what are the sizes of effects and how precise are they? It
has been suggested that a trial is informativewhen it allows us
to determine with confidence that an intervention is either
effective or ineffective, and uninformative when—owing to
the confidence interval being so wide (and precision so
low)—it is consistent with the intervention being effective,
ineffective, or harmful (Lortie-Forgues and Inglis 2019). If a
clear picture emerges, suggesting little reason for optimism, it
is likely to steer responses a different way (for example, to-
wards discontinuation or modification) than if there is uncer-
tainty or even a glimmer of hope (in which case protagonists
might advocate conducting another, typically larger, trial).
Next, the context in which the trial was conducted and its
similarity to the context in which results are to be interpreted
and applied is likely to affect how different stakeholders re-
spond. There has been a growing appreciation of the impor-
tance of the external validity of trials in recent years, such that
questions are frequently raised about whether what works
there will work here (Cartwright and Hardie 2012). Usually,
debate centers on whether or not to import programs found to
be effective in other countries, but equally we might ask how
much weight to assign to a null effect trial in a different so-
cioeconomic, political, cultural, or organizational context, or
whether a null or negative effect in a “home” context counts
for more than several positive “away” trials.
A further factor related to trial design that we hypothesize
will affect how stakeholders respond to null or negative effects
is the extent to which it generated insights that help to explain
the results. Many—until recently, most—prevention trials fo-
cus on the effect on outcomes and pay less attention to process
and mechanisms. This is changing (see below, also Moore
et al. 2015), but arguably having a sense of why something
was ineffective or harmful makes it easier to accept the result
and learn from the findings.
Last is the nature of the control condition. Some trials com-
pare a modified version of an intervention with the original
(the control), or pitch the intervention of interest against a
similar intervention (a so-called “head-to-head” trial). In the
case of the former, the failure to add value to the original may
make it easy to discontinue the modified version, while in the
latter, a null effect may be interpreted positively (the interven-
tion is not inferior) and lead to continuation of the
intervention.
Context for decision-making
One aspect of the context in which the trial results are reported
is the evidence base.Whether the trial in question is the first of
the intervention or the newest of several arguably has an effect
on how stakeholders respond to the findings. Specifically, a
null or negative result produced by the sole evaluation might
be construed by some as a disaster, but the same result could
be shrugged off if the trial is one of a series on the same
program and earlier high-quality studies yielded overwhelm-
ingly positive results. For instance, several EBPs with null
effect trials in the UK, such as Functional Family Therapy
(Humayun et al. 2017) and Multisystemic Therapy (Fonagy
et al. 2018), nevertheless achieve the highest rating on the
Early Intervention Foundation Guidebook4 owing to a pre-
ponderance of evidence in their favor from other studies.
Then, there is the wider evidence base. If there are studies of
similar interventions, their outcomes and the contexts in
which they took place will shape the interpretation of disap-
pointing findings. For example, a null effect might be taken as
reason to discontinue an intervention if there is accumulating
evidence that other approaches are more beneficial.
Another aspect of context relates to policy and practice
imperatives. There may be a legal or moral obligation to do
something to address the problem that the unsuccessful inter-
vention seeks to tackle, or a lack of choice of other evidence-
based approaches in the field. Decisions about what to do next
with an intervention following a null or negative effect trial are
clearly different in these circumstances compared with a situ-
ation where there is no obligation to intervene or a range of
options from which to choose.
There is also the political and economic context. In a cli-
mate of public sector austerity, for instance, or faced with an
external shock such as the Covid-19 pandemic, the need to
respond to a problem quickly using the limited resources at
one’s disposal usually takes precedence over careful consid-
eration of the evidence. It would not be surprising, therefore, if
an intervention shown in a trial to be ineffective continued to
be implemented instead of more effective alternatives, espe-
cially if the latter cost more.
Perspectives and Interests
The final set of factors revolves around the individuals con-
cerned and, at a collective level, the organizations or interests
they represent. Their perception of the aforementioned
factors—the intervention, the study, and the context in which
decisions are to be made—is shaped by their position, expe-
riences, interests, beliefs, and predispositions. At the simplest
level, program developers, funders, commissioners, practi-
tioners, and evaluators all face different pressures and, as such,
sometimes have competing priorities. It is difficult to disen-
tangle how these play out, but we hypothesize that a critical
factor will be how much individuals and the bodies they rep-
resent have invested in the intervention, whether financially,
psychologically, organizationally, or politically. For example,
4 The Guidebook is a UK-based registry of prevention and early intervention
programs: https://guidebook.eif.org.uk
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practitioners are likely to have a stronger stake in a currently
commissioned intervention than a new innovation developed
by researchers; they may consider that an embedded and val-
ued intervention has a legitimacy that should not be overrid-
den by results from a trial. Some interventions are even syn-
onymous with the organization that developed or delivers
them, in which case a null or negative effect trial could have
far-reaching repercussions at both structural and personal
levels (such as loss of livelihood). It is much harder for indi-
viduals in those organizations to advocate discontinuing the
intervention than it is for a dispassionate service commission-
er needing to demonstrate value for money, or even an aca-
demic developer whose intervention exists primarily for re-
search purposes.
The extent to which stakeholders endorse the value of trials
as a robust means of generating evidence will also affect their
response to null or negative effect trial results. A skeptic might
not be overly concerned, preferring instead to prioritize other
types of evidence or evaluation methods.
Towards a More Constructive Approach
We recognize the interactive and dynamic nature of the factors
outlined above, which makes it difficult to identify any single
factor that explains how stakeholders respond to null or neg-
ative trial results. As researchers, we need to be sympathetic to
and mindful of the conflict such results might create between
and within stakeholders at many levels. For this reason, it is
necessary to enable and support open and honest but poten-
tially difficult conversations that take account of the wider
context in which interventions are (or are not) implemented.
Even so, some responses to null or negative trial results are
arguably more constructive than others. So how do we culti-
vate a stronger culture of learning in response to evidence that
an intervention was ineffective or harmful, and in so doing
foster a climate for intervention design and testing that encour-
ages learning for the field (i.e., beyond benefit for that specific
intervention)?
In the Appendix, we set out a series of actions that can help
to achieve this goal. Some pre-empt the problem by minimiz-
ing the likelihood of conducting null or negative effect trials.
Others are concerned with preparing for such results so that
learning is maximized should they materialize. The remainder
focus on acknowledging and sharing null or negative effects
and minimizing the temptation to manipulate or dismiss them.
Collectively, they span the chronology of a trial from its in-
ception through design and conduct to reporting; the right
steps taken early on make it easier to act appropriately later.
While some actions are arguably novel, several are advocated
by others as part of best practice in developing and evaluating
complex interventions (e.g., Craig et al. 2008; Davies 2013),
in which case we seek to highlight their value in the current
context. We would also argue that the actions are mutually
reinforcing. For example, the process of considering results
openly and honestly is more likely if efforts have beenmade to
foster a collegiate learning culture. Broadly the actions iden-
tified fall into five categories.
Culture
It is necessary to cultivate a learning culture among key stake-
holders, that is, those people who will shape the decision
about what to do with the intervention following the trial.
This requires agreeing why the trial is being conducted, name-
ly to learn about an intervention’s effectiveness and factors
that contribute to this, with a view to improving the quality
of services provided for children and families. The influence
may be direct. For instance, provisionmay be enhanced by the
incorporation of the intervention if it is found to be effective,
or by efforts to improve the intervention if the results are
equivocal or disappointing, or by replacing it with something
that is more effective. Lessons from the evaluation may also
contribute to services more indirectly through being picked up
in systematic reviews or meta-analyses, which in turn have the
potential to shape policy and practice. While achieving con-
sensus among key stakeholders about trial purpose and value
may be challenging, failure to do so will seriously undermine
efforts to respond appropriately to the results should they be
null or negative.
A learning culture can further be enhanced by managing
expectations about results, namely the possibility of null or
negative results (based on precedent), and by articulating like-
ly and unlikely scenarios, such as the relatively common ex-
perience of seeing some effects on some measures of some
outcomes and the rare experience of finding large effects on
most outcomes. In order to reinforce a sense of openness and
realism among stakeholders, it may help to develop outline
plans for communicating positive, mixed, null, or negative
results publicly. The overarching aim is to counter the errone-
ous belief that the trial will unquestionably prove the interven-
tion to be effective and thereby give it a ticket to scale.
The aim should also be to encourage a collegiate culture, so
that investigators and key stakeholders, especially program de-
velopers, feel that they are working together on a shared en-
deavor. This requires early and ongoing consultation, partly to
understand different perspectives, motivations, and needs and
thereby identify potential tensions but also to discuss trial de-
sign and conduct. For example, agreeing outcome constructs
and measures before the trial commences guards against the
temptation to criticize or regret the choice of measures post
hoc once disappointing results are known and thereby under-
mine confidence in the null or negative effect. Failure to work
together can create an adversarial culture in which, for instance,
the deliverers of the intervention feel “done to” or under
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surveillance, which in turn contributes (unsurprisingly) to a
reticence to accept and act on results.
Process
In addition to working collaboratively, learning from null or
negative results is more likely if the process of conducting the
trial is done carefully and thoughtfully. There are various as-
pects to this. First, a definitive trial should only proceed if it is
clearly necessary and appropriate, meaning that all of the fol-
lowing apply: (i) it has a plausible evidence-informed theory
of change; (ii) potential harms have been considered and ruled
out; (iii) intervention feasibility and acceptability have been
established; (iv) there is genuine uncertainty about interven-
tion effectiveness relative to the control (“equipoise”); (v) al-
ternative methods of impact evaluation are unsuitable; and (vi)
key stakeholders agree that a null or negative result is as wor-
thy, interesting, and publication-worthy as a positive result. If
an established or scaled intervention lacks a sound theory of
change, efforts should be made to develop one retrospectively
before proceeding to a trial, for example through an
evaluability assessment (Davies 2013). Moreover, since many
purportedly “innovative” interventions are highly derivative,
it is arguable that testing their effectiveness in a definitive trial
is unlikely to tell us anything important that we do not already
know. In these cases, time and effort would be better spent
improving the intervention so that it better embodies features
known to be associated with or predictive of stronger effects.
For example, a structured approach to doing this has been
used to strengthen juvenile justice provision (Lipsey et al.
2010).
Second, conducting an internal or external pilot trial affords
the opportunity to “fail” early, quickly, and insignificantly
when the stakes are low and learn the lessons from this, so
minimizing the likelihood of “failing” late, slowly, and at
considerable cost and time in a definitive trial when the stakes
are higher. For example, if a pilot trial indicates that the re-
quired sample size to detect a statistically significant effect in
the main trial is too big for the planned recruiting sites to
manage, this can be addressed by increasing the number of
trial clusters or even abandoning the move to a definitive trial
if cost and feasibility outweigh benefit (e.g., Segrott et al.
2015). Additionally, if the pilot uncovers problems with re-
cruitment processes or the precision of the outcome measure,
both of which could increase the probability of a null effect
trial, then remedial action can be taken.
Third, if a definitive trial proceeds, it should be terminated
early if appropriate. Developing and, if necessary, applying
“early stopping rules” means that if it becomes apparent dur-
ing the trial that there is likely to be a null or negative effect,
for example owing to poor uptake or implementation prob-
lems, the study can be ended early, thereby minimizing re-
search waste and potential harm to participants. In doing this,
it is important that sequential analyses are conducted in order
to avoid ending a trial prematurely based on incorrectly pre-
dicted futility and thereby inflating type I error rates.
Fourth, results need to be considered by members of the
trial team and other stakeholders in a way that encourages
dispassionate and thoughtful analysis. Specifically, process
evaluation results should be shared first, allowing time for
discussion about implementation fidelity in order to hypothe-
size why the interventionmay or may not have worked and for
whom, with outcome results only being shared second and,
critically, without initially revealing the identity of the trial
arms. To our knowledge, this is not common practice, but
based on our own (VB) and col leagues ’ recent
experiences—in the E-SEE and Engager trials respectively
(Bywater et al. 2018; Kirkpatrick et al. 2018)—we contend
that it promotes less biased reflection on findings, and discour-
ages the tendency to search for reasons to explain away dis-
appointing outcome results.
Fifth, results need to be reported openly and fairly, in other
words to accept them for what they are and share them with
others. Minimizing the temptation to manipulate or dismiss
results in the ways described above starts by setting parame-
ters early in the process. Thus, we should state success criteria
before the trial commences, register the trial, publish the pro-
tocol, and put in the public domain an analysis plan that aligns
with the protocol. This increases accountability by limiting the
opportunity to bury undesirable findings or give undue weight
to effects on secondary outcomes or for subgroups. Critically,
the results need to be published, and in line with best practice
(Grant et al. 2018). If it proves impossible to get the paper
accepted in a high-impact journal, options include submitting
it to a journal that operates “results-free” peer review, meaning
that acceptance is based on methodological quality rather than
findings, or one specializing in null result studies (e.g.,
Journal of Articles in Support of the Null Hypothesis). Other
repositories include PsychFileDrawer.org, which focuses on
“serious replication attempts in all research areas of
psychology—whether they succeeded or failed” and encour-
ages online discussion of findings.
Intervention Design
Much has been written about good intervention design else-
where (for a review, see O’Cathain et al. 2019), so here we
highlight only a few points. One is the importance of drawing
on relevant literature that has been appraised carefully and is
deemed to be reliable. This, in turn, requires that the quality of
basic research is improved, for instance through study pre-
registration, better data sharing, and more replication research
(Lortie-Forgues and Inglis 2019). Next, design is likely to be
further strengthened by building trusting relationships with
intervention developers, professional development providers,
and people with lived experience of the issue targeted by the
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intervention and collaborating with them in a process of
human-centered co-design (Lyon and Koerner 2016). A fur-
ther consideration should be intervention context, specifically
the factors (e.g., political, organizational, cultural, social, eco-
nomic, geographical, financial) that are anticipated to impact
on implementation and therefore outcomes. An implementa-
tion research framework (e.g., Damschroder et al. 2009) and
guidance on how to take account of context in intervention
research (Craig et al. 2018) could usefully inform this exer-
cise, shaping both intervention design and implementation
strategy. Lastly, possible unintended adverse effects of the
intervention (which may contribute to null or negative effects)
should be considered and the design adjusted accordingly
(Bonell et al. 2015). In addition to asking stakeholders to
consider likely adverse effects freely and without prompting,
it can be useful to work together through common types such
as psychological stress, widening health inequalities, deviancy
training, and opportunity costs (Lorenc and Oliver 2013).
Trial Design
Trial design has a significant bearing on the extent to which
the results are conducive to learning. Several steps can be
taken tominimize the likelihood of results leaving ambiguities
in the event of null or negative effects, thereby making them
more informative. Equally, certain actions enable the explora-
tion and therefore potential elimination of competing explana-
tions for an intervention being ineffective or harmful, thereby
pointing to possible improvements or practices to avoid.
The first is ensuring that the study is adequately powered,
either by increasing sample size if practical or, if not, by fo-
cusing on more targeted subgroups or using more targeted
outcome measures (Lortie-Forgues and Inglis 2019). This
helps to avoid finding no effect because the sample was too
small. Second, it pays to record carefully the services received
by control arm participants. If they significantly exceed those
received by intervention participants, or resemble the inter-
vention, it may help to account for null or negative effects.
Third, the timing of follow-up points should be calibrated
according to theoretical and empirical evidence on when out-
comes are likely to be observed. If an effect on the primary
outcome is not expected until 12 months post-intervention,
this data collection point should be in the study design.
Fourth, statistical mediation analysis (O’Rourke and
MacKinnon 2018) and qualitative techniques such as contri-
bution analysis (Mayne 2008) can be used to explore whether
the theory of change has materialized in practice, which may
help explain null or negative effects. Fifth, all aspects of fidel-
ity need to be recorded, including delivery (dose, adherence,
quality, responsiveness), implementer training, and the degree
to which participants enact what the intervention focuses on
(Borrelli 2011). This helps with determining if and how poor
fidelity accounts for a lack of effect. Sixth, there is much value
in conducting pre-specified ancillary analyses that explore the
relationship between outcomes on the one hand and sample
characteristics and fidelity on the other. This involves suffi-
ciently powered subgroup analyses to explore whether some
types of participant benefit more than others, and complier
average causal effect (CACE) analysis, which compares
“compliers” in the intervention arm with a comparable group
in the control arm (Hewitt et al. 2006). Finally, robust data
should be gathered on implementation context, as this affects
intervention effectiveness (Craig et al. 2018), and possible
adverse or neutralizing effects (see above). Many of the sug-
gested actions here align with the trend towards mixed
methods and realist trials (Hesse-Biber 2012; Bonell et al.
2012), which move from answering “Does it work?” to “For
whom does it work, why and in what context?”
Environment
As indicated earlier, the behavior of investigators and key
stakeholders is shaped by multiple incentives and constraints.
For this reason, their ability to enact our recommendations
demands a suitable infrastructure and supporting climate.
This requires collaboration from a number of actors besides
investigators and program developers (the audience for most
of the preceding recommendations).
First, funders need to be willing to pay for feasibility stud-
ies and pilot trials, and for “thicker” trials that incorporate
robust process evaluations and analyses of mediators, moder-
ators, and fidelity x outcome interaction effects. They should
also fund—and indeed insist on—protocol sharing and publi-
cation of results, regardless of what form they take. If invest-
ment in trials is seen as part of a developmental process, there
is also a case for a guaranteed “improvement fund” should re-
design be the preferred option or a protected “decommission
fund” if an established intervention is deemed to have no
future. While these suggestions have cost implications,
funders can save money by being more selective about the
trials they fund, which might include paying for evaluations
that use other methods where suitable.
Second, publishers—supported by journal editors and edi-
torial boards—need to make it easier to publish null and neg-
ative trial results. Strategies might include results-free peer
review or accepting results papers “in principle” on accep-
tance of a protocol article. Additional steps to support honest
reporting of results and reduce potentially biased post hoc
critique of methods include only publishing trial results if
the protocol and analysis plan are in the public domain, mak-
ing more space available in journals for trial protocols, and
allowing room in journals for authors and critics to debate the
merits of a given trial design before results are known (Chan
and Hróbjartsson 2018).
Third, intermediary organizations concerned with promot-
ing research utilization could play a valuable role in
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supporting developers and purveyors with intervention de-
sign, improvement, and evaluation. This includes helping
them to develop interventions that are less likely to produce
null or negative effects, which might entail assistance with
finding and applying existing research evidence in the context
of a human-centered co-design process. It might also involve
adapting interventions sensibly in the light of disappointing
findings, or encouraging the use of evaluation methods that
contribute to intervention improvement rather than
progressing prematurely to a trial.
Fourth, EBP registries should encourage the appropriate
generation and use of evidence. This might entail providing
credit for robust evidence of a null or negative effect and
issuing guidance on how to weigh such evidence, for example
highlighting that depending on other factors (see above) it
need not mean discontinuing the intervention. It could also
involve providing stronger ratings for well-conducted non-tri-
al impact evaluations that nevertheless go some way towards
attributing causal inference, and highlighting programs that
display features or common elements of effective interven-
tions (even if they have not themselves been evaluated exper-
imentally). These steps would mitigate the pressure felt by
developers and purveyors to subject their intervention to a trial
prematurely in order to attain a rating that will, they believe,
increase its likelihood of being commissioned.
Lastly, academic institutions could credit investigators who
share trial protocols (Chan and Hróbjartsson 2018) and pub-
lish null or negative trial results.
Conclusion
We have sought to recast null or negative trial results as some-
thing to learn from, not fear. The learning should be for the
field and not restricted to the intervention in question. This
depends on trials being designed and conducted with a learn-
ing mindset and in a commissioning and policy climate that
encourages innovation and experimentation and reduces asso-
ciated disincentives. There is also a need for researchers,
funders, and developers to reflect on the fact that while simple
behavioral interventions are easier to implement and to eval-
uate through trials, they are less likely to work in tackling
complex social and health problems with complex causes
(Ghate 2016; Rutter et al. 2017). In other words, the system
that encourages such activity inadvertently increases the like-
lihood of null effect trials.
More empirical research is needed into how stakeholders
manage and respond to null and negative effect trials and the
factors that predict this, since this will help with understanding
the barriers to and facilitators of learning. This should entail a
combination of desk-based research to code responses to null
or negative effect trials and in-depth interviews with key
stakeholders about post-trial decision-making to illuminate
what happened and why. We also plan to conduct a Delphi
exercise to synthesize multiple stakeholders’ perspectives on
our recommendations with a view to producing guidance for
investigators. In the meantime, we look forward to a time
when there will be fewer but more informative null and neg-
ative effect trials—essentially more mixed method trials of
potentially ground-breaking innovations—and a stronger em-
phasis on applying the lessons from such studies to embedded
practice.
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Appendix. Recommended actions to promote
learning from null and negative effect trials in
prevention science5
A. Culture
Foster a learning culture among key stakeholders by:
– [1] agreeing pre-trial that the goal is to help improve
population health outcomes, whether through the selected
or other interventions, and learning how best to do this
– [2] agreeing the opportunities for learning (i.e., questions
the trial will help answer)
– [3] managing expectations about outcomes (e.g., possibil-
ity of null or negative results)
– [4] planning for how to interpret and communicate re-
sults, whatever form they take
Foster a collegiate culture by:
5 Sections A, B, C, and D are aimed at investigators and program developers,
while section E is aimed at other actors.
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– [5] engaging from the outset in regular and ongoing con-
sultation about decisions regarding the intervention and
trial
B. Process
Proceed carefully, thoughtfully, and collaboratively, so
that:
– [6] a definitive trial is only conducted if necessary and
appropriate, by:
& [i] developing a clear and logical theory of change
& [ii] considering potential harms and either putting in place
mitigating actions or redesigning the intervention to re-
duce or eliminate potential harms
& [iii] establishing intervention feasibility and acceptability
& [iv] ensuring that there is genuine uncertainty about inter-
vention effectiveness relative to the control (“equipoise”)
& [v] obtaining consensus among key stakeholders that a
null or negative result is as interesting, useful, and
publication-worthy as a positive result
& [vi] considering and ruling out alternative (non-trial)
methods of impact evaluation
– [7] the trial is terminated early if appropriate, by develop-
ing and, if necessary, applying early stopping rules
– [8] results are considered in an honest way, by sharing
process evaluation results within the research team first,
then sharing the outcome results (blind to trial arm in the
first instance)
– [9] results are reported openly and fairly, by:
& [i] stating success criteria before the trial commences, in
particular the primary outcome(s) and minimum effect
size that is of practical significance
& [ii] registering the trial on a relevant online database, pub-
lishing the trial protocol, and developing (and making
publicly available) a detailed analysis plan (statistical
and qualitative) that aligns with the protocol
& [iii] publishing the results as fully and in as publicly ac-
cessible a way as possible
C. Intervention design
Design the intervention in such a way that it is less
likely to have a null or negative effect, more likely to
be suitable for the context and more likely to be imple-
mented well, by:
– [10] drawing on literature that has been appraised as be-
ing reliable to inform the intervention design
– [11] co-designing the intervention with practitioners, pro-
fessional development providers, and people with lived
experience of the issue
– [12] identifying at the outset possible unintended adverse
effects that might contribute to null or negative effects,
and either redesigning the intervention completely or
making adaptations accordingly
– [13] understanding and taking account of context and
the system in which the intervention will be
implemented
D. Trial design
Design and conduct the trial in such a way that it is:
– [14] less likely to leave ambiguities and more likely to be
informative, by:
& [i] ensuring the study is adequately powered
& [ii] recording what intervention and control group partic-
ipants are receiving by way of the intervention and other
(non-intervention) services
& [iii] calibrating follow-up data collection time points based
on theory and empirical evidence on when effects are ex-
pected to be observed
& [iv] gathering robust data on all aspects of fidelity
& [v] exploringmechanisms of impact both qualitatively and
quantitatively
& [vi] undertaking pre-specified and sufficiently powered
moderator analyses
& [vii] undertaking appropriate fidelity x outcome analyses
& [viii] gathering robust data on implementation context
– [15] less open to post hoc criticism, by agreeing measures
and other aspects of design a priori (see above)
– [16] alert to possible adverse effects or at least neutraliz-
ing influences, by gathering appropriate data on such in-
fluences and undertaking relevant analyses
E. Environment
Enable all of the above by cultivating an infrastructure and
climate that incentivize desired behaviors and disincentivize
undesired behaviors on the part of investigators and program
developers. This involves the following:
– [17] funders paying for: feasibility and pilot studies;
“thicker” trials with substantial process evaluations and
ancillary analyses; protocol sharing; open access results
publication; alternative evaluation methods where suit-
able; post-trial action plans
– [18] academic publishers: mandating protocol publication
prior to trial results publication; making more space for
protocol sharing and debate on trial methods as specified
in protocols; making space for publication of statistical
analysis plans; offering results-free peer review; and
accepting trial results articles “in principle” at the point
of accepting a protocol for publication
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– [19] intermediary organizations: providing support and
training with intervention design/adaptat ion;
and assisting developers and purveyors with service im-
provement and evaluation
– [20] registries of EBPs providing credit for: interventions
subjected to a high-quality null effect trial; non-trial im-
pact evaluation; and non-trialed programs assessed as
displaying key features of effective programs
– [21] academic institutions crediting investigators who share
trial protocols and publish null or negative trial results
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